{
  "drug_name": "Isoniazid",
  "url": "https://wikem.org/wiki/Isoniazid",
  "scraped_at": "2026-01-10T07:55:51.209212",
  "sections": {
    "Administration": {
      "text": "Type: Anti-\nTB\nDosage Forms:\nRoutes of Administration: PO, IM\nCommon Trade Names: INH",
      "subsections": {},
      "tables": [],
      "links": [
        {
          "text": "TB",
          "url": "https://wikem.org/wiki/TB"
        }
      ]
    },
    "Adult_Dosing": {
      "text": "Typically 5 mg/kg (or 300mg) daily",
      "subsections": {},
      "tables": [],
      "links": []
    },
    "Pediatric_Dosing": {
      "text": "â‰¤40 kg: 10-15 mg/kg daily, maximum 300mg/dose\n>40kg: 5 mg/kg daily max 300mg/dose",
      "subsections": {},
      "tables": [],
      "links": []
    },
    "Special_Populations": {
      "text": "",
      "subsections": {
        "Pregnancy_Rating": {
          "text": "Category A",
          "tables": []
        },
        "Lactation_risk": {
          "text": "Considered compatible with breast feeding\n[1]",
          "tables": []
        },
        "Renal_Dosing": {
          "text": "No adjustment",
          "tables": []
        },
        "Hepatic_Dosing": {
          "text": "No official adjustment necessary per manufacturer's labeling but use with caution in patient's with preexisting liver disease",
          "tables": []
        }
      },
      "tables": [],
      "links": []
    },
    "Pregnancy_Rating": {
      "text": "Category A",
      "subsections": {
        "Lactation_risk": {
          "text": "Considered compatible with breast feeding\n[1]",
          "tables": []
        },
        "Renal_Dosing": {
          "text": "No adjustment",
          "tables": []
        },
        "Hepatic_Dosing": {
          "text": "No official adjustment necessary per manufacturer's labeling but use with caution in patient's with preexisting liver disease",
          "tables": []
        }
      },
      "tables": [],
      "links": []
    },
    "Lactation_risk": {
      "text": "Considered compatible with breast feeding\n[1]",
      "subsections": {
        "Renal_Dosing": {
          "text": "No adjustment",
          "tables": []
        },
        "Hepatic_Dosing": {
          "text": "No official adjustment necessary per manufacturer's labeling but use with caution in patient's with preexisting liver disease",
          "tables": []
        }
      },
      "tables": [],
      "links": []
    },
    "Renal_Dosing": {
      "text": "No adjustment",
      "subsections": {
        "Hepatic_Dosing": {
          "text": "No official adjustment necessary per manufacturer's labeling but use with caution in patient's with preexisting liver disease",
          "tables": []
        }
      },
      "tables": [],
      "links": []
    },
    "Hepatic_Dosing": {
      "text": "No official adjustment necessary per manufacturer's labeling but use with caution in patient's with preexisting liver disease",
      "subsections": {},
      "tables": [],
      "links": []
    },
    "Contraindications": {
      "text": "Allergy/hypersensitivity to class/drug\nPrior history of hepatic injury or severe adverse reaction to isoniazid\nAcute liver disease",
      "subsections": {},
      "tables": [],
      "links": []
    },
    "Adverse_Reactions": {
      "text": "",
      "subsections": {
        "Common": {
          "text": "Increased serum transaminases",
          "tables": []
        }
      },
      "tables": [],
      "links": []
    },
    "Serious": {
      "text": "",
      "subsections": {
        "Common": {
          "text": "Increased serum transaminases",
          "tables": []
        }
      },
      "tables": [],
      "links": []
    },
    "Common": {
      "text": "Increased serum transaminases",
      "subsections": {},
      "tables": [],
      "links": []
    },
    "Pharmacology": {
      "text": "Half-life: Fast acetylators: 30 to 100 minutes, slow acetylators: 2 to 5 hours\nMetabolism: Hepatic\nExcretion: Mostly urine",
      "subsections": {},
      "tables": [],
      "links": []
    },
    "Mechanism_of_Action": {
      "text": "Inhibits synthesis of mycoloic acids (essential bacterial cell wall component)",
      "subsections": {},
      "tables": [],
      "links": []
    },
    "See_Also": {
      "text": "Isoniazid toxicity",
      "subsections": {},
      "tables": [],
      "links": [
        {
          "text": "Isoniazid toxicity",
          "url": "https://wikem.org/wiki/Isoniazid_toxicity"
        }
      ]
    },
    "References": {
      "text": "Nahid P, Dorman SE, Alipanah N, et al. Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis. Clin Infect Dis. 2016;63(7):e147-e195.\nUptodate",
      "subsections": {},
      "tables": [],
      "links": []
    }
  }
}